What is HC Wainwright’s Estimate for CNTB FY2030 Earnings?

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – Research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Connect Biopharma in a report issued on Monday, January 26th. HC Wainwright analyst B. Folkes anticipates that the company will post earnings of ($0.11) per share for the year. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share.

Connect Biopharma (NASDAQ:CNTB) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07).

A number of other analysts have also recently weighed in on CNTB. BTIG Research reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Connect Biopharma in a report on Thursday, November 13th. Lake Street Capital initiated coverage on shares of Connect Biopharma in a research report on Monday, December 1st. They issued a “buy” rating and a $9.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Connect Biopharma in a research note on Wednesday, January 21st. Finally, Wall Street Zen raised Connect Biopharma to a “hold” rating in a research note on Saturday, December 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.67.

Connect Biopharma Price Performance

Shares of NASDAQ CNTB opened at $2.48 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.48 and a quick ratio of 5.48. The firm has a market capitalization of $138.63 million, a PE ratio of -3.40 and a beta of -0.19. Connect Biopharma has a 1-year low of $0.51 and a 1-year high of $3.28. The business’s fifty day moving average price is $2.52 and its two-hundred day moving average price is $2.07.

Institutional Investors Weigh In On Connect Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of CNTB. XTX Topco Ltd acquired a new position in shares of Connect Biopharma in the 2nd quarter worth approximately $29,000. Koa Wealth Management LLC acquired a new position in shares of Connect Biopharma in the 2nd quarter worth $49,000. Finally, AlphaCore Capital LLC purchased a new position in Connect Biopharma in the 2nd quarter worth about $78,000. 58.72% of the stock is owned by institutional investors and hedge funds.

Connect Biopharma Company Profile

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.